Presentation Ross Cohen Great. Thank you all for joining us today, and welcome to the Morgan Stanley Healthcare Conference. Just a quick note on disclosures. For important disclosures, please see the Morgan Stanley research disclosure website. Or if you have any questions, please reach out to your Morgan Stanley sales representative. So welcome to the group here, and thank you for attending the fireside for MannKind. My name is Ross Cohen. I'm an Executive Director from the Morgan Stanley Healthcare Inves ...

Company Overview - MannKind has been in operation for 34 years, originally focusing on inhalation therapeutics and diabetes [5] - The company has undergone significant changes in the past month, indicating a shift in its strategic direction [5] Strategic Focus - Over the last 7 to 8 years, MannKind has diversified away from its primary focus on diabetes [5] - The company is now concentrating on applying its inhalation technology in areas that can create the most impact for shareholders, patients, and employees [5]